RankingsPricing
  1. JP-listed companies
  2. Kringle Pharma,Inc.
  3. Financials
  4. Cash and cash equivalents

Kringle Pharma,Inc.JP:4884

Market cap
¥2.6B
P/E ratio
-2.3x
SummaryFinancialsHistoryOwnershipWorkforce
Period EndCash and cash equivalents (Million JPY)YoY (%)
Sep 30, 20251,619-30.01%
Sep 30, 20242,313+8.28%
Sep 30, 20232,136-22.49%
Sep 30, 20222,756+28.95%
Sep 30, 20212,138+1.66%
Sep 30, 20202,103+1162.97%
Sep 30, 2019166-67.05%
Sep 30, 2018505

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)